ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX) Files An 8-K Regulation FD Disclosure
Item7.01.
| Regulation FD Disclosure. |
On June14, 2017, management of Aldeyra Therapeutics, Inc.
(Aldeyra) will hold a conference call at 8:00 am ET to discuss
data from its randomized, dose-ranging, parallel-group,
double-masked, vehicle-controlled, conjunctival allergen
challenge Phase 2b clinical trial of 0.1% and 0.5% ADX-102
ophthalmic solution. A copy of the presentation being used in
connection with this conference call is furnished herewith as
Exhibit 99.1 and is incorporated by reference herein.
The information in this Item7.01 of this Current Report on Form
8-K, including Exhibit 99.1 attached hereto, shall not be deemed
filed for purposes of Section18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in any such filing.
| Item8.01. | Other Events. |
On June14, 2017, Aldeyra issued a press release announcing data
from its randomized, dose-ranging, parallel-group, double-masked,
vehicle-controlled, conjunctival allergen challenge Phase 2b
clinical trial of 0.1% and 0.5% ADX-102 ophthalmic solution. A
copy of Aldeyra press release is attached hereto as Exhibit 99.2
and is incorporated by reference herein.
| Item9.01. | Financial Statements and Exhibits. |
(d)Exhibits
|
Exhibit No. |
Description |
|
| 99.1 | Aldeyra Therapeutics, Inc. Presentation dated June 14, 2017 | |
| 99.2 | Aldeyra Therapeutics, Inc. Press Release dated June 14, 2017 |
About ALDEYRA THERAPEUTICS, INC. (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.
